探索人类骨髓衍生单核细胞对体外血管生成的影响
Judith A H M Peeters1,2, Hendrika A B Peters1,2, Anique J Videler1,2
1Department of Surgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
International journal of molecular sciences
|September 28, 2023
概括
治疗慢性四肢缺血的骨髓细胞疗法显示不太有前途. 这项研究没有发现证据表明骨髓衍生单核细胞 (BM-MNCs) 促进内皮细胞中的血管生长,这表明任何观察到的益处的替代机制.
科学领域:
- 再生医学是一种再生医学.
- 血管生物学 血管生物学
- 细胞疗法细胞疗法
背景情况:
- 慢性肢体威胁性缺血 (CLTI) 是一种严重的疾病,治疗选择有限.
- 骨髓衍生单核细胞 (BM-MNCs) 正在研究用于CLTI治疗,但其疗效和机制尚不清楚.
- 血管新生,即新血管的形成,是CLTI的潜在治疗点.
研究的目的:
- 为了研究人类骨髓细胞分离物对内皮细胞的直接和膜血管效应.
- 为了在仿真缺血症的正常和缺氧条件下评估这些效应.
- 确定BM-MNCs是否促进内皮细胞的增殖,迁移,管道形成和大动脉环生长.
主要方法:
- 在人静脉内皮细胞 (HUVEC) 的体外分析.
- 评估内皮细胞增殖,迁移和管形成的测试.
- 大动脉环生长试验,以评估血管生成.
- 在正常和缺氧条件下进行的实验.
主要成果:
- 在用BM-MNCs治疗的HUVEC中没有观察到显著的血管效应.
- 没有证明BM细胞分离物对内皮细胞血管生成的直接或近影响.
- 该研究没有发现BM-MNCs促进内皮细胞增殖,迁移或管形成的证据.
结论:
- 实验室实验表明,对于CLTI患者的BM-MNC治疗的潜在益处可能无法通过内皮细胞血管生成进行调解.
- 这项研究提供了有限的证据,支持在CLTI的背景下BM-MNCs的血管新生机制.
- 需要进一步的研究,以阐明 BM-MNCs 在 CLTI 中的治疗效果背后的精确机制.
更多相关视频
09:21Isolation and Intravenous Injection of Murine Bone Marrow Derived Monocytes
Published on: December 27, 2014
23.8K
10:32Author Spotlight: Simple Establishment of a Vascularized Osteogenic Bone Marrow Niche Using Pre-Cast Poly(Ethylene Glycol) (PEG) Hydrogels in an Imaging Microplate
Published on: May 19, 2023
2.6K
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Mechanism of Angiogenesis
5.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K
